1. Introduction {#sec1}
===============

An acute stress response is necessary for survival; it facilitates adaptation to external stressors and primes the body for the metabolic, physical and cognitive demands of *fight-or-flight* ([@bib56]). Although classically assessed by HPA axis and sympathetic nervous system (SNS) activation, the stress response also involves precise changes in neuronal plasticity ([@bib56]) along with central and peripheral immune activation ([@bib91], [@bib90]). When the behavioral response to physical, psychological or metabolic stressors becomes maladaptive, profound consequences upsetting physical health and mental wellbeing occur ([@bib10]). Nearly half of Americans report experiencing at least one psychiatric disorder at some point in their lives, the most common being depression ([@bib39], [@bib40]). Mounting evidence supports a causal link between stress-induced activation of the *Kynurenine Pathway* and psychiatric disorders, including depression ([@bib64], [@bib75], [@bib97]) and schizophrenia ([@bib9], [@bib82]). Stress can also trigger depression, as well as influence the length and severity of depressive episodes ([@bib27]). Similarly, stress is a comorbid factor for schizophrenia ([@bib35]). Thus, advancing our understanding of the mechanism(s) by which the brain responds to stress serves to elucidate the biology underpinning stress-related psychiatric disease.

Tryptophan (Trp) metabolism via the *Kynurenine Pathway* is initiated by three rate-limiting dioxygenases, DOs ([@bib55]). Acute predatory stress ([@bib62]), foot shock ([@bib81]) and physical restraint or immobilization ([@bib26]) increase DO activity and mRNA expression in the brain and liver. The general dogma is that glucocorticoids regulate Tdo2 expression, while Ido1 and Ido2 are regulated by inflammatory mediators ([@bib49], [@bib55]). Indeed, early work on stress and the *Kynurenine Pathway* focused on the activation of hepatic Tdo2 (a.k.a. tryptophan pyrrolase) associated with HPA axis activation ([@bib2], [@bib72], [@bib88], [@bib89]). Acute restraint-stress increases hepatic Tdo2 mRNA expression and activity ([@bib26]) mediated in part by adrenocortical secretions ([@bib72]). Acute stress also increases Ido1 expression in the brain ([@bib41], [@bib94]) and periphery ([@bib41]). Nevertheless, there is only one report of stress regulating Ido2 expression in the CNS ([@bib8]), although its unique role in immunophysiology is established ([@bib59]).

Stress is associated with immunological changes both in the periphery and CNS ([@bib21], [@bib90]). Acute stress increases brain cytokine levels including TNFα ([@bib53], [@bib76]) and IL-1β ([@bib69], [@bib68]). These cytokines synergistically regulate *Kynurenine Pathway* activity ([@bib22], [@bib23]). The pro-inflammatory effects of stress in the CNS is well established ([@bib91], [@bib90]) and it has been demonstrated that cytokine induction is necessary for Ido1 upregulation by stress ([@bib41], [@bib51]). Although some work has investigated the regulation of DOs by stress within the CNS and periphery, the cellular origins responsible for DO induction remain undefined.

Kynurenine itself is not considered a neuroactive metabolite ([@bib55]), albeit increased DO activity is required for depression-like behaviors following stress ([@bib26], [@bib51]). Instead, Kyn is further metabolized down the *Kynurenine Pathway* into other neuroactive metabolites, i.e. kynurenines. This is especially relevant to the CNS owing to the remarkable cellular specificity in the production of kynurenines ([@bib55]). Most notably, astrocytes are enzymatically equipped to produce kynurenic acid (KynA) a glutamate (NMDA) and acetylcholine (α~7~nACh) receptor antagonist ([@bib30], [@bib98]), while microglia produce quinolinic acid (QuinA) and 3-hydroxykynurenine (3-HK) which are NMDA receptor agonists ([@bib32], [@bib34]). A recent study found that chronic unpredictable stress increased central Ido1 and Tdo2 mRNA coincident with increased KynA concentrations, but unchanged 3-HK ([@bib13]). This would suggest a specific role for astrocytes in stress-induced DO induction.

Herein we report induction of all three DOs by acute restraint-stress specifically within astrocytes. We have expanded on recent work investigating DO-regulation by stress ([@bib94]) to include the regulation of recently described alternatively-spliced DO mRNA transcripts ([@bib6], [@bib7]). Moreover, since acute stress increases Kyn levels in both plasma and brain ([@bib38], [@bib81]), we include DO-regulation by stress in liver, the major tryptophan metabolizing organ primarily via Tdo2. Finally, since there is evidence of changes in Ido2 expression within Ido1-knockout (Ido1^KO^) mice ([@bib24], [@bib50]), we expanded our study to include stress-induced DO-regulation in brain, astrocytes and liver of Ido1^KO^ mice.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

C57BL/6J (wild-type) or Ido1^KO^ mice (The Jackson Laboratory, Bar Harbor, ME, USA) were used to establish breeding colonies to supply male mice for experiments. Mice were housed on a reversed 12 h light-dark cycle with *ab lib* access to food and water. Mice were individually housed at least 1 week prior to experiments. Mice were 14--15 weeks of age at the time of treatment. All animal procedures were approved by the Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council).

2.2. Study design {#sec2.2}
-----------------

### 2.2.1. Restraint-stress {#sec2.2.1}

Restraint-stress was initiated at the onset of the dark cycle (10 a.m.) and maintained for 3 h using ventilated syringes ([@bib93]). Mice were euthanized 2 h after the cessation of restraint, at which time wild-type mice had a significant reduction in body weight associated with restraint-stress (control change in body weight 0.1 ± 0.1 g vs. restrained −0.9 ± 0.1 g, p \< 0.001). A similar response was seen with Ido1^KO^ mice (control 0.4 ± 0.1 g vs. restrained −0.7 ± 0.2 g, p \< 0.001).

Following euthanasia, caval blood was collected into heparinized syringes. Samples were centrifuged and plasma collected. Mice were intracardially perfused using cold PBS plus 2 mM EDTA. After perfusion, samples were collected from separate cohorts of mice for either 1) whole brain sampling followed by glia enrichment or 2) brain region and liver collection as described in sections [2.2.2](#sec2.2.2){ref-type="sec"}, [2.2.3](#sec2.2.3){ref-type="sec"}, respectively.

### 2.2.2. Brain sampling and glia enrichment: mouse cohort 1 {#sec2.2.2}

Brains were removed and placed in ice-cold Hank\'s balanced salt solution then homogenized with a GentleMACS dissociator using Neural Tissue Dissociation kits (130-093-231, Miltenyi Biotec Inc.) per manufacturer instructions. Immediately after homogenization, an aliquot of 'brain' was removed and stored in TRIzol (15596018, Ambion by Life Technologies) for later RNA isolation. The \'brain\' samples were collected from homogenates before removal of astrocytes and microglia and thus represent expression by all cells and all brain regions in their original proportion. Remaining homogenate was demyelinated by centrifugation in 20% i**s**otonic Percoll (E0414-1L, Sigma-Aldrich, St. Louis, MO). The cell pellet was re-suspended then partitioned into two fractions for positive-selection using either anti-Cd11b (130-093-634) or anti-Glast labeling microbeads (130-095-826). Microglia (Cd11b^+^) and astrocytes (Glast^+^) were enriched using MACS MS magnetic separation columns. Microglia and astrocyte populations were suspended in TRIzol and stored at −80 °C for later RNA isolation ([@bib48]). Glia enrichment was verified by comparing Glast1 and Cd11b mRNA expression to the \'brain\' homogenate from which they were derived. Glast1 expression was greater in enriched astrocytes compared to brain in wild-type mice (5.9 ± 0.4-fold, p \< 0.001) and Ido1^KO^ mice (12.0 ± 1.0-fold, p \< 0.001). Cd11b expression was greater in microglia preparations compared to brain from wild-type mice (265.6 ± 10.8-fold, p \< 0.001).

### 2.2.3. Brain region and liver collection: mouse cohort 2 {#sec2.2.3}

Brain-regions (prefrontal cortex (PFC), striatum (Stri), hippocampus (Hippo), hypothalamus (Hypo)) and livers were collected and frozen for later RNA extraction. The remaining brain (sans PFC, Stri, Hippo and Hypo) was frozen for analysis of Kyn.

2.3. Gene expression by qPCR {#sec2.3}
----------------------------

RNA was extracted from brain, astrocytes, microglia, PFC, Stri, Hippo, Hypo and liver, then reverse-transcribed (4368813, Applied Biosystems). Resulting cDNA was used for quantitative polymerase chain reaction (qPCR) using TaqMan Universal PCR Master Mix (4324020, Applied Biosystems). Expression of each test gene were normalized to the reference gene (Gapdh) using the 2^−ΔΔCt^ method ([@bib52]). Gene expression in naïve control (Ctrl) brain or Ctrl PFC is set to 1.0, with samples from the same experiments expressed relative to appropriate controls. Gene structure and mRNA transcripts for the DOs are shown in [Fig. 1](#fig1){ref-type="fig"}. Assays designed to quantify the various DO transcripts are described in [Table 1](#tbl1){ref-type="table"}. PCR was performed with probe-based assays (IDT, Coralville, Iowa). Custom assays were designed using the IDT PrimerQuest^®^ Design Tool. Assays for Kat2 (Mm.PT.49.16077568), Kmo (Mm.PT.56.31570400), Kynu (Mm.PT.56.12643855) and Haao (Mm.PT.58.29327685) were predesigned by IDT. Because of low expression, some transcripts are \'not detected\' (i.e. C~t~ values 'undetermined') thus preventing calculation of relative gene expression following induction; for analysis a C~t~ value of 40.0 is assigned when this occurs.Fig. 1**Gene structure and transcripts for murine Ido1, Ido2 and Tdo2**. Like human DOs, murine DO gene-processing results in the expression of multiple mRNA transcripts. Our previous ([@bib6], [@bib7]) and current work clearly show distinct transcripts are utilized to fine-tune regulation of the *Kynurenine Pathway*.Fig. 1Table 1Assay specifics for analysis of murine Ido1, Ido2 and Tdo2 steady-state gene expression.Table 1[^1]

2.4. Kynurenine levels by high performance liquid chromatography (HPLC) {#sec2.4}
-----------------------------------------------------------------------

Brain samples were suspended in ice cold buffer (0.1 N perchloric acid + 25 μM ascorbic acid) at 200 mg wet weight/ml and disrupted by sonication. Samples were incubated for 30 min then centrifuged at 12,000 *g* for 5 min at 4 °C. Supernatants were collected and loaded into Spin-X filters (Corning, NY, USA) and centrifuged at 10,000 *g* for 5 min at 4 °C. Filtrates were used for HPLC analysis. Plasma samples were processed for analysis by HPLC as previously reported ([@bib101]). HPLC mobile phase consisted of 75 mM monosodium phosphate (pH 4.6), 25 μM EDTA and 0.01% triethylamine prepared in either 4.5 or 6% acetonitrile for brain and plasma extracts, respectively. Chromatogram peaks were integrated using EZChrom SI software (Agilent Technologies, Santa Clara, CA, USA). Kyn standards were made to encompass levels in the samples.

2.5. Statistics {#sec2.5}
---------------

Two-way ANOVA was used to compare the relative expression of genes between astrocytes, microglia and brain, and to compare brain-regions and liver, while T-tests were used to determine the effects of stress. Analysis was performed using SigmaPlot 14.0 software. Significance was set at p ≤ 0.05.

3. Results {#sec3}
==========

3.1. Acute stress increases gene expression of markers for HPA axis activation and inflammation {#sec3.1}
-----------------------------------------------------------------------------------------------

FK506-binding protein 51 (Fkbp5) expression was increased by restraint-stress in both brain and liver ([Fig. 2](#fig2){ref-type="fig"}A). These data confirm a HPA axis response ([@bib92], [@bib100]). Some effects of restraint-stress are mediated by increases in pro-inflammatory cytokines. Restraint-stress increased IL-1β ([Fig. 2](#fig2){ref-type="fig"}B) and Tnfα ([Fig. 2](#fig2){ref-type="fig"}C) expression within brain, confirming an inflammatory response. Although relative expression of IL-1β and Tnfα was higher in liver vs. brain, a stress-induced inflammatory response was not observed in liver. Also, IFNγ gene expression was unaffected by restraint-stress in brain and liver. IFNγ protein concentrations in plasma from naïve and restrained mice were below detection-limits (data not shown).Fig. 2**Acute stress increases gene expression of markers for stress and inflammation**. Perfused brain and liver tissue obtained from wild-type (WT) control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 3 h restraint were used to assess **(A)** HPA activation by quantifying Fkbp5 expression and an inflammatory response by quantifying **(B)** IL-1β and **(C)** Tnfα expression. \*p \< 0.05 Ctrl vs. Res.Fig. 2

3.2. Acute stress increases plasma and brain kynurenine in wild-type, but not Ido1^KO^ mice {#sec3.2}
-------------------------------------------------------------------------------------------

[Plasma concentrations]{.ul} of Kyn were increased by restraint-stress in wild-type, but not Ido1^KO^ mice ([Fig. 3](#fig3){ref-type="fig"}A). [Brain concentrations]{.ul} of Kyn were also increased by stress in wild-type, but not Ido1^KO^ mice ([Fig. 3](#fig3){ref-type="fig"}B). Since the DOs are rate-limiting enzymes in the metabolism of Trp to Kyn ([@bib55]), these data verify restraint-stress activation of the *Kynurenine Pathway* and the necessity of Ido1 for increased Kyn.Fig. 3**Acute stress increases plasma and brain kynurenine in wild-type, but not Ido1**^**KO**^**mice**. Two hours after a three hour restraint-stress **(A)** plasma and **(B)** brain from WT and Ido1^KO^ mice were analyzed for kynurenine (Kyn) by HPLC. \*p \< 0.05 comparing control (Ctrl) to restraint-stress (Res) samples.Fig. 3

3.3. Acute stress increases Ido1-v1 expression in astrocytes and select brain-regions {#sec3.3}
-------------------------------------------------------------------------------------

Ido1 expression in the mouse brain is reported to both increase and remain unchanged following acute stress. Based on our nomenclature ([Fig. 1](#fig1){ref-type="fig"}), these studies used PCR assays amplifying either Ido1-FL ([@bib8], [@bib41]) or all Ido1 transcripts simultaneously, Ido1-Tot ([@bib26]). We independently quantified expression three Ido1 transcripts to refine this issue. In agreement with our previous work ([@bib7]), Ido1-FL and Ido1-v2 transcripts were poorly expressed in brains and livers of naïve mice. Their expression was not induced by restraint-stress (data not shown).

[Ido1-v1]{.ul} is well expressed in the mouse brain and numerically, but [non]{.ul}-significantly, elevated by restraint-stress ([Fig. 4](#fig4){ref-type="fig"}). Initially, this suggests that Ido1-v1 expression is not altered by restraint-stress; however, a more in-depth investigation reveals the nature of Ido1-v1 expression. Ido1-v1 expression is induced 4.8-fold in astrocytes, but not in microglia, isolated from stressed mice. The stress effect is not only cell-type specific but brain-region specific, disguising significant effects when whole-brain is assessed. Ido1-v1 expression was highest in striatum followed by hypothalamus relative to other brain-regions. Restraint-stress increased Ido1-v1 in prefrontal cortex and hypothalamus. As expected, Ido1^KO^ mice did not express Ido1-v1 ([Fig. 4](#fig4){ref-type="fig"}), Ido1-FL or Ido1-v2 (not shown). Hepatic expression of Ido1-FL, Ido1-v1 and Ido1-v2 was low and not altered by stress. Thus, Ido1 expression exhibits brain-region, glial and transcript-specificity within naïve and restrained wild-type mice.Fig. 4**Acute stress increases Ido1-v1 expression in astrocytes and select brain-regions**. Tissue and glia from control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 3 h restraint were analyzed for Ido1-v1 expression. Expression was quantified in whole-brain, glia, liver and several brain-regions: the prefrontal cortex (PFC), striatum (Stri), hippocampus (Hippo) and hypothalamus (Hypo). Samples from Ido1^KO^ mice did not express any Ido1 transcript. Ido1-FL and Ido1-v2 transcripts were not detected by qPCR. \*p \< 0.05 comparing Ctrl to Res within tissue or glia. ^ϕ^p\<0.05 compared to other brain-regions.Fig. 4

3.4. Acute stress increases Ido2-v3 expression in astrocytes {#sec3.4}
------------------------------------------------------------

To our knowledge, there is only one report examining the effect of stress on Ido2 expression. Using an assay that detects all transcripts (Ido2-Tot), forced-swimming-associated stress increased hippocampal Ido2 expression in BALB/c, but not C57BL/6J, mice ([@bib8]). We quantified expression of Ido2 ([Fig. 1](#fig1){ref-type="fig"}) for transcript-, tissue- and glial-specific responses between naïve and restrained mice. Of eight Ido2 mRNA variants, restraint-stress remarkably increased the expression of only one Ido2 transcript; this transcript-specificity would make it difficult to detect changes when simultaneously quantifying all transcripts, i.e. Ido2-Tot.

[Ido2-FL]{.ul} is poorly expressed in the naïve mouse brain except within the striatum where Ido2-FL expression is 10-fold higher ([Fig. 5](#fig5){ref-type="fig"}A) than other brain-regions. In striking contrast, hepatic Ido2-FL is markedly higher in relation to brain-regions. While restraint-stress had no effect on central Ido2-FL, hepatic Ido2-FL expression in wild-type and Ido1^KO^ mice was decreased following restraint.Fig. 5**Acute stress increases Ido2-v3 expression in astrocytes**. Tissue and glia from control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 3 h restraint were analyzed for **(A)** Ido2-FL, **(B)** Ido2-v3 and **(C)** Ido2-v4 expression. \*p \< 0.05 comparing Ctrl to Res within tissue or glia. ^ϕ^p\<0.05 compared to other brain-regions. ^δ^p\<0.05 liver compared to all brain-regions.Fig. 5

[Ido2-v3]{.ul} is well expressed in the mouse brain, but stress-induced changes are not realized when analyzing whole-brain or brain-regions ([Fig. 5](#fig5){ref-type="fig"}B). The low basal expression in astrocytes and microglia relative to brain indicates that most of the Ido2-v3 in naïve brain is expressed by stress-insensitive cells. Nonetheless, Ido2-v3 expression is increased by stress 13-fold in astrocytes. In Ido1^KO^ mice, Ido2-v3 expression by astrocytes is not increased by stress. In wild-type mice, hepatic expression of Ido2-v3 is greater relative to brain-regions; and hepatic Ido2-v3 is decreased by stress, albeit significant only for Ido1^KO^ mice.

[Ido2-v4]{.ul} is also poorly expressed in the naïve mouse brain except within the striatum ([Fig. 5](#fig5){ref-type="fig"}C) where Ido2-v4 expression is highest ([@bib7]). Again, hepatic expression of Ido2-v4 is markedly higher in relation to brain-regions. While not regulated by stress within the brain, stress decreased hepatic Ido2-v4 expression in wild-type and Ido1^KO^ mice.

Thus, expression of Ido2-FL, Ido2-v3 and Ido2-v4 are stress sensitive, lowered in liver and Ido2-v3 is elevated in astrocytes. Other Ido2 transcripts exhibit unique patterns of expression across tissues and brain-regions, but their expression is relatively independent of stress ([Supplementary Fig. S1](#appsec1){ref-type="sec"}).

Compared to wild-type mice, the brains of Ido1^KO^ mice are strikingly deficient in several Ido2 transcripts, including 78% reduction in Ido2-v3 ([Fig. 5](#fig5){ref-type="fig"}B), 84% reduction in Ido2-v1, 92% reduction in Ido2-v2, 22% reduction in Ido2-v5, 57% reduction in Ido2-v6 and loss of detectable Ido2-v7 ([Fig. S1](#appsec1){ref-type="sec"}). This loss of Ido2 in Ido1^KO^ is cell- and tissue-specific, and was previously reported to occur in B-lymphocytes, but not liver ([@bib59]). We confirm their finding showing that relative expression of various Ido2 transcripts is similar in the liver between wild-type and Ido1^KO^ mice ([Fig. 5](#fig5){ref-type="fig"} and [Fig. S1](#appsec1){ref-type="sec"}). The decrease in Ido2-v3 within brains of Ido1^KO^ mice is not mediated astrocytes, as Ido2-v3 in astrocytes from Ido1^KO^ mice is numerically greater than astrocytes from wild-type mice. Thus, loss of Ido2-v3 occurs in another cell-type within the brain. Additionally, although Ido2-v3 is induced by stress in astrocytes from wild-type mice, it was not increased in Ido1^KO^ mice. Thus, the regulation of Ido2 is transcript-, tissue- and cell-type-specific in wild-type mice, and genetic deletion of Ido1 perturbs central Ido2 expression. Importantly, when interpreting physiologic differences between wild-type and Ido1^KO^ mice, diminished Ido2 expression in the brain should be considered.

3.5. Acute stress increases Tdo2-FL expression in brain, astrocytes and liver {#sec3.5}
-----------------------------------------------------------------------------

Tdo2 was the first DO investigated within the context of acute stress with early reports describing increases in hepatic Tdo2 activity ([@bib11], [@bib67], [@bib72]). However, Tdo2 expression in the frontal cortex of the rat brain was unchanged after acute stress despite an increase of Tdo2 in liver using a qPCR assay that quantified all Tdo2 transcripts, i.e. Tdo2-Tot ([@bib26]). The current report is the first to quantify the regulation of the three known Tdo2 transcripts ([Fig. 1](#fig1){ref-type="fig"}) in stressed mice to identify distinct regulatory profiles.

[Tdo2-FL]{.ul} expression is increased to 2.3-fold of controls in brain by restraint-stress ([Fig. 6](#fig6){ref-type="fig"}A). This effect is paralleled by a 1.8-fold increase within astrocytes. Tdo2-FL expression in microglia is lower than brain and astrocytes and unaffected by stress. Tdo2-FL expression within astrocytes from Ido1^KO^ mice was also doubled by restraint-stress, but not within the brains from which they were derived. Astrocyte Tdo2-FL expression is greater in Ido1^KO^ mice compared to the brain of wild-type mice, suggesting genetic deletion of Ido1 results in specific compensatory Tdo2-FL upregulation within astrocytes. Although stress increased Tdo2-FL expression in brain from wild-type mice, stress did not increase Tdo2-FL in brain of Ido1^KO^ mice. This finding suggests another brain cell-type, possibly neurons ([@bib49]), expressing Tdo2-FL is only stress-sensitive when Ido1 is intact. Tdo2-FL is considerably higher in the liver relative to brain-regions and increased by stress in both wild-type and Ido1^KO^ mice.Fig. 6**Acute stress increases Tdo2-FL expression in liver, brain and astrocytes**. Tissue and glia from control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 3 h restraint were analyzed for **(A)** Tdo2-FL, **(B)** Tdo2-v1 and **(C)** Tdo2-v2 expression. \*p \< 0.05 comparing Ctrl to Res within tissue or glia. ^ϕ^p\<0.05 compared to other brain-regions. ^δ^p\<0.05 liver compared to all brain-regions.Fig. 6

[Tdo2-v1]{.ul} is increased to 10.1-fold of controls by restraint-stress in brains from wild-type mice ([Fig. 6](#fig6){ref-type="fig"}B). Although Tdo2-v1 expression is greater in astrocytes and microglia relative to whole-brain, its expression in these cells is unaffected by restraint. These data suggest the stress-induced increase in brain Tdo2-v1 is mediated by neurons (or other glia) which also express Tdo2 ([@bib49]). Unlike Tdo2-FL, Tdo2-v1 expression is similar across brain-regions. Thus, these data illustrate a unique expression pattern vs. Tdo2-FL (despite the entire Tdo2-FL sequence encompassed within Tdo2-v1, [Fig. 1](#fig1){ref-type="fig"}). Like Tdo2-FL, there is no increase in brain Tdo2-v1 expression in Ido1^KO^ mice, indicating a requirement of Ido1 for brain Tdo2-v1 induction. In wild-type mice, hepatic Tdo2-v1 expression is greater than in brain-regions, but not significantly affected by restraint-stress.

[Tdo2-v2]{.ul} expression in brain of wild-type mice is increased 7.3-fold by restraint-stress ([Fig. 6](#fig6){ref-type="fig"}C). Tdo2-v2 expression in both astrocytes and microglia is greater than brain levels, yet unaffected by restraint. Like Tdo2-v1, these data suggest the stress-induced increase in brain Tdo2-v2 is mediated by neurons or other glia. Tdo2-v2 expression in astrocytes from Ido1^KO^ mice is decreased slightly but significantly by restraint. Tdo2-v2 expression is similar across brain-regions. In wild-type mice, Tdo2-v2 levels in liver were greater than brain-regions and increased by restraint.

Therefore, all three Tdo2 transcripts are increased by restraint-stress in brains of wild-type mice. The increase in brain Tdo2-FL parallels the increase in astrocytes, whereas the increases in Tdo2-v1 and Tdo2-v2 are mediated by unidentified cell-types. Only Tdo2-FL and Tdo2-v2 are increased by restraint-stress in liver relative to control mice. Thus, there is transcript-, tissue- and cellular-specificity of Tdo2 expression and regulation by restraint-stress.

3.6. Other *Kynurenine Pathway* related gene expression & regulation by stress {#sec3.6}
------------------------------------------------------------------------------

The DOs are rate-limiting for Trp metabolism to Kyn, but Kyn itself is further metabolized into neuro- and immune-active kynurenines in a cell-specific manner. This specificity is achieved by differential expression of enzymatic machinery downstream of the DOs ([@bib12]). Thus, we expanded our analysis to include enzymes further along the *Kynurenine Pathway*.

[Kat2]{.ul} (kynurenine-2-oxoglutarate aminotransferase) converts Kyn to KynA. Kat2 expression is enriched in astrocytes compared to microglia and highly expressed in liver. Within brain regions, Kat2 expression is highest in the hypothalamus; however, Kat2 expression is unaffected by stress ([Fig. 7](#fig7){ref-type="fig"}A). These data confirm previous reports of astrocyte enrichment of Kat2 ([@bib28], [@bib42], [@bib83]).Fig. 7**Other *Kynurenine Pathway* related gene expression & regulation by stress**. Tissue and glia from control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 3 h restraint were analyzed for **(A)** Kat2, **(B)** Kynu, **(C)** Kmo and **(D)** Haao expression. \*p \< 0.05 comparing Ctrl to Res within tissue or glia. ^ϕ^p\<0.05 compared to other brain-regions. ^δ^p\<0.05 liver compared to all brain-regions.Fig. 7

[Kynu]{.ul} (kynureninase) initiates Kyn metabolism to QuinA. Kynu expression is greater in microglia relative to astrocytes and considerably higher in liver ([Fig. 7](#fig7){ref-type="fig"}B). These data confirming previous reports of microglial enrichment of this enzyme within the brain ([@bib31], [@bib30]). Kynu expression is highest in the hypothalamus with expression largely unaffected by stress, the exception being a decrease in the hippocampus.

[Kmo]{.ul} (kynurenine 3-monooxygenase) also initiates Kyn metabolism to QuinA. Kmo expression is greater in microglia relative to astrocytes, but again considerably higher in liver. These data confirm previous reports of microglial enrichment of this enzyme in the brain ([@bib31], [@bib30]). Kmo expression is increased ∼50% in astrocytes and ∼20% in microglia by stress ([Fig. 7](#fig7){ref-type="fig"}C).

[Haao]{.ul} (3-hydroxyanthranilate 3,4-dioxygenase) acts downstream of Kynu and Kmo to complete QuinA synthesis. Haao expression is greater in microglia relative to astrocytes, but again considerably higher in liver. Haao expression is slightly but significantly decreased by stress in both microglia and liver ([Fig. 7](#fig7){ref-type="fig"}D). Again, these data confirm preferential expression of Haao by microglia in the brain ([@bib30], [@bib34]).

The extremely high levels of Tdo2, Ido2 and especially the downstream enzymes within the liver (relative to brain), attest to its ability to efficiently generate niacin and NAD ([@bib4]). Overall, since the DOs are considered rate-limiting in the *Kynurenine Pathway,* these changes in downstream enzymes probably do not result in an overall shift in the relative ability to produce downstream kynurenines; that is to say astrocytes will generate primarily KynA and microglia QuinA as limited by Kyn production by the DOs.

4. Discussion {#sec4}
=============

Acute restraint-stress increased the expression of all three DOs within the mouse brain in a transcript-, tissue- and cell-type specific manner. Brain and plasma levels of Kyn were found to be increased in stressed mice relative to controls demonstrating a functional increase in DO activity following acute restraint-stress. Remarkably, Ido1-v1, Ido2-v3 and Tdo-FL expression was increased by stress in astrocytes, but not microglia. However, in comparison to wild-type mice, we found aberrant Ido2 and Tdo2 expression in Ido1^KO^ mice demonstrating a necessity of Ido1 for normal Ido2 and Tdo2 regulation within the brain. The expression patterns of downstream *Kynurenine Pathway* enzymes confirm the hypothesis that astrocytes are central producers of KynA while microglia are equipped to produce primarily QuinA. Since only astrocyte DO expression was increased by stress, these finding further implicate a key role for Kyn and KynA within the neurobiology of stress-induced behaviors.

4.1. Acute stress increases gene expression of markers for stress and inflammation {#sec4.1}
----------------------------------------------------------------------------------

The induction of Fkbp5 by restraint-stress in brain and liver ([Fig. 2](#fig2){ref-type="fig"}A) confirm glucocorticoid receptor activation ([@bib92], [@bib100]). However, restraint-stress increased brain, but not liver, expression of pro-inflammatory cytokines, Tnfα and IL-1β ([Fig. 2](#fig2){ref-type="fig"}B--C), confirming previous reports of increases in brain IL-1β ([@bib69], [@bib68]) and circulating TNFα and IL-1β following stress, without coincident changes in the liver ([@bib77]). While both the HPA axis and autonomic nervous system contribute to the induction of peripheral and central pro-inflammatory cytokines following stress ([@bib91], [@bib90]), the pro-inflammatory cytokines TNFα ([@bib1]) and IL-1β ([@bib14]) also increase glucocorticoid release. Extending our understanding by which inflammatory mediators are regulated by the stress response (or vice versa) is out of the scope of this study; however, we are interested in how these confirmed stress responses affect the *Kynurenine Pathway*.

4.2. Acute stress increases plasma and brain kynurenine in wild-type, but not Ido1^KO^ mice {#sec4.2}
-------------------------------------------------------------------------------------------

Following acute stress, increases in central and peripheral Kyn concentrations have been independently verified ([@bib38], [@bib41], [@bib63], [@bib62], [@bib77], [@bib81]). Our data reaffirm acute-stress increases both brain and plasma Kyn and further demonstrates the necessity of Ido1 for restraint-stress-induced increase in Kyn ([Fig. 3](#fig3){ref-type="fig"}A--B). Although Ido1 is intimately involved in elevated Kyn levels associated with inflammation ([@bib74]), Ido2 and Tdo2 also have this capability ([@bib49]). Thus, the inability of stress to induce Ido2-v3 and Tdo2 variants in Ido1^KO^ mice may also be involved in the lack of Kyn induction in Ido1^KO^ mice.

4.3. Acute stress increases Ido1-v1 expression in astrocytes and select brain-regions {#sec4.3}
-------------------------------------------------------------------------------------

Ido1 expression is increased by inflammatory mediators ([@bib7], [@bib55], [@bib95]) and synergistically by inflammatory mediators plus corticosteroids, although in a transcript-specific manner ([@bib7]). Within the brain and liver of naïve mice, Ido1-FL and Ido1-v2 expression was extremely low, similar to our previous report ([@bib7]). Ido1-FL and Ido1-v2 expression were not increased by restraint-stress in the current study; however, a previous study observed a 14-fold increase in whole-brain Ido1-FL following acute combined acoustic and restraint-stress of female BALB/c mice ([@bib41]). Whether the difference between that of Kiank and our study is due to a stronger stressor (acoustic + restraint vs. restraint), different mouse strain (BALB/c vs. C57BL/6J) or sex (female vs. male) is open to debate. Basal Ido1 expression by astrocytes from BALB/c mice may be greater than that of C57BL mice, permitting detection of Ido1 induction in whole brain by stress. Independent of this, Ido1-FL and Ido1-v2 are inducible *in vivo* by inflammatory signals such as LPS ([@bib6], [@bib74]) and Ido1-FL induction in the mouse brain by mycobacterium infection is IFNγ-dependent ([@bib73]). Since IFNγ was not increased in our acute-stress model, Ido1-FL was not induced. Thus, our data clearly suggest that [neither]{.ul} Ido1-FL nor Ido1-v2 mediate the stress-induced Kyn levels in the brain of C57BL/6J mice.

Ido1-v1 is the major Ido1 transcript within the naïve mouse brain, and its expression is increased by LPS *in vivo* ([@bib6]) and IFNγ *ex vivo* ([@bib7]). IFNγ also induces Ido1-Tot expression in astrocytes ([@bib47]) and microglia ([@bib99]). However, the current data suggest IFNγ-[in]{.ul}dependent stimuli must be responsible for Ido1-v1 induction in astrocytes by stress. Although Ido-v1 was not increased by stress in whole-brain, its expression was increased by stress in the frontal cortex and hypothalamus ([Fig. 4](#fig4){ref-type="fig"}), likely within astrocytes. The significance of the cortex and hypothalamus sensitivity to restraint-induced Ido1-v1 induction relative to behavior remains to be determined.

Astrocytes are a heterogeneous population of related cells ([@bib29]) varying in functionality across brain-regions ([@bib87]). Previous reports assessing Ido1-Tot indicated primary cultures of murine astrocytes do not express Ido1 ([@bib47]). By contrast, we detected Ido1-v1 expression in freshly isolated astrocytes, albeit at lower levels compared to the brains from which they were isolated. Thus, the distribution of Ido1 transcripts is cell-type specific. Astrocytes are not the major source of central Ido1-v1, but a 4.8-fold induction by stress could be critical to changes in astrocyte Kyn and KynA production.

We detected minimal expression of Ido1 transcripts in liver which were unaffected by restraint-stress; however, Ohta found increased hepatic Ido1-Tot following 6 h of water-immersion restraint-stress. This was associated with increased hepatic and serum IFNγ ([@bib77]). Thus, it is possible that our acute stress was insufficient for inducing IFNγ necessary for hepatic Ido1 induction.

4.4. Acute stress increases Ido2-v3 expression in astrocytes {#sec4.4}
------------------------------------------------------------

Ido2 expression in the brain and liver is consistent with our previous report ([@bib7]). For example, Ido2-FL is enriched in the striatum, yet its expression is highest in liver ([Fig. 5](#fig5){ref-type="fig"}A). Sets of Ido2 transcripts share expression patterns: Ido2-FL and Ido2-v4 are enriched in striatum, while Ido2-v1, Ido2-v2, Ido2-v3, Ido2-v5 and Ido2-v6 are enriched in hypothalamus, but Ido2-v8 was not detected in the brain ([Fig. 5](#fig5){ref-type="fig"} and [Fig. S1](#appsec1){ref-type="sec"}). The cell-types responsible for these differences are unknown. Cells within distinct brain-regions must either differently splice Ido2 pre-RNA to generate different transcripts or utilize different promoter regions to initiate transcription thereby generating different transcripts. The same can be said for Ido1 and Tdo2 transcript profiles, albeit Ido2 is the most complex.

Mazarei found enriched expression of both Ido1-Tot and Ido2-Tot in striatum and that Ido1^KO^ mice were deficient in Ido2-Tot within the striatum ([@bib54]), reflecting our expression pattern for Ido1-v1 or Ido2-FL, Ido2-v4 and Ido2-v6, respectively ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"} and [Fig. S1](#appsec1){ref-type="sec"}). Moreover, unlike wild-type mice, Ido2-v3 expression was not increased by stress in Ido1^KO^ mice ([Fig. 5](#fig5){ref-type="fig"}B), further highlighting the dysregulation of Ido2 within the brain in the absence of Ido1. These findings raise the issue as to whether behavioral changes seen with Ido1^KO^ mice may also be dependent on reduced basal Ido2 expression and the non-inducible nature of Ido2 in Ido1^KO^ mice. This is important, as Ido1 is considered anti-inflammatory, whereas Ido2 acts as a pro-inflammatory facilitator most likely via an enzymatic-[in]{.ul}dependent mechanism ([@bib57]).

Astrocytes and microglia also differentially express Ido2 transcripts. Ido2-v3 ([Fig. 5](#fig5){ref-type="fig"}B) was the only Ido2 transcript upregulated by stress and this only occurred within astrocytes. When cloned and overexpressed, the enzymatic activity of the protein encoded by Ido2-v3 was less than that from Ido2-FL ([@bib59]). Thus, the enzymatic or non-enzymatic role that stress-responsive Ido2-v3 plays in animal behavior, brain function and Kyn production remains to be determined.

In the current study, both astrocytes and microglia were found to express all three DOs, albeit to varying degrees. However, the DOs may not be universally co-expressed. As an example, within the liver Ido2 and Tdo2 are constitutively expressed by mature hepatocytes ([@bib24], [@bib36]), whereas low but interferon-γ-inducible Ido1 expression is found within hepatic stellate cells ([@bib45]). This pattern may explain the abundant relative expression of Ido2 and Tdo2 compared to Ido1 found by liver in the current study. One of the critical issues under investigation by several laboratories is the need for this segregation. The three DOs have redundant enzymatic activity (i.e. Trp→Kyn metabolism) but they also have non-redundant functions such as Ido1-non-enzymatic mediated self-tolerance ([@bib79]) and Ido2-pro-inflammatory mediation of autoimmunity ([@bib57]). Clearly in the current work, restraint-stress induces specific Ido1, Ido2 and Tdo2 transcripts within astrocytes while decreasing Ido2 and increasing Tdo2 in liver. Whether these regulatory profiles result in distinct cellular functions is unknown and warrants consideration. Compared to brain, liver greatly over-expresses Ido2-FL, Ido2-v3, Ido2-v4 and Ido2-v8, consistent with previous reports of abundant hepatic Ido2 protein ([@bib24]) and mRNA ([@bib7]). In contrast, Ido2-v1, Ido2-v2, Ido2-v5 and Ido2-v6 expression levels are higher in all brain-regions compared to liver ([Fig. 5](#fig5){ref-type="fig"} and [Fig. S1](#appsec1){ref-type="sec"}). These data clearly illustrate the utilization of alternative-gene processing to produce distinct Ido2 transcript profiles. The ability to fine-tune the Ido2 transcriptome endows the brain and liver with precise regulatory control for responding differentially to stressors.

Hepatic Ido2 expression did not appear to differ significantly between wild-type and Ido1^KO^ mice, although [@bib43] found decreased Ido2 expression in inguinal lymph nodes of Ido1^KO^ mice. Nevertheless, stress resulted in decreased hepatic Ido2-FL, Ido2-v3 and Ido2-v4 and striatal Ido2-v1. Again, the functional consequences of these tissue-specific changes on behavior remain undetermined.

Determining the mechanism behind perturbed (diminished) expression of specific Ido2 transcripts in Ido1^KO^ mice is outside the scope of the current study. Ball et al. hypothesized that, since Ido1 and Ido2 are adjacent on mouse (and human) chromosome 8 (Tdo2 is on murine chromosome 3), the excision of the 3 exons and intervening introns of the Ido1 gene ([Fig. 1](#fig1){ref-type="fig"} top) may perturb Ido2 expression by disrupting cis-regulatory elements ([@bib3]). The Ido1 gene (spanning 13 kbp) is located 5′ of Ido2 (spanning 22 kbp) with less than 8 kbp\'s separating the two genes on both the mouse and human chromosomes. While both promoters and enhancer elements are short DNA sequences (typically 100 bp and 50--1500 bp, respectively), promoters are generally very near the transcription start site (TSS). In contrast, enhancer elements may be located far (\>100,000 bp) upstream of the TSS ([@bib44]). Thus, enhancers controlling Ido2 expression could easily reside within the upstream Ido1 gene. Thus far, we are unaware of any reports identifying upstream regulatory elements involved in Ido2 expression. However, future studies utilizing the commercially available Ido1^KO^ mouse model should consider the involvement of both altered Ido2 expression (current work and [@bib3], [@bib59]) and activity ([@bib59]).

Similar to murine Ido2, alternative transcripts for human IDO2 have been described with transcripts lacking various exons or initiating at exon 1 or 2 ([@bib15], [@bib58]). Human IDO2 transcripts containing exon 10 are widely expressed across tissues including liver and brain, but those amplified with a forward primer in exon 1a plus reverse primers in either exon 8 or exon 10 are limited to placenta and brain ([@bib58]). Although not confirmed by qPCR analysis, alternate transcripts for human IDO1 and TDO2 have been described ([@bib16], [@bib17]). Thus, DO expression and regulation in humans is most likely also transcript-, tissue- and cell-specific. Characterization of human DO transcript regulation by inflammatory or stress-related signals has not been reported.

4.5. Acute stress increases Tdo2-FL expression in brain, astrocytes and liver {#sec4.5}
-----------------------------------------------------------------------------

Our data ([Fig. 6](#fig6){ref-type="fig"}A--C) support previous reports of abundant hepatic expression of Tdo2 relative to the brain ([@bib7], [@bib37]) as well as the upregulation of Tdo2 mRNA in liver by restraint-stress ([@bib26], [@bib77]) and in brain-slice cultures by glucocorticoids ([@bib7]). However, this is the first report describing the stress-induced upregulation of hepatic Tdo2-FL and Tdo2-v2 and of all three functionally characterized Tdo2 transcripts ([@bib37]) within whole-brain. However, stress did not induce Tdo2 transcripts in selected brain-regions (PFC, Stri, Hippo and Hypo). Similarly, Gibney reported no acute stress-induced change in Tdo2-Tot mRNA within the PFC ([@bib26]), further implicating other brain-regions such as the cerebellum or brain stem ([@bib37], [@bib54], [@bib81]) in the central Tdo2 transcriptional response to acute restraint-stress.

Shimazu first reported increased hepatic Tdo2 activity (*in vitro* conversion of Trp to Kyn by liver homogenate) following peripheral administration of corticosterone, or by stimulation of the hypothalamic sympathetic nucleus, both effects seemingly [in]{.ul}dependent of adrenal secretions. However, hepatic Tdo2 enzymatic activity was greater when the hypothalamus of animals with intact adrenals were stimulated ([@bib88]). Indeed, the addition of the synthetic glucocorticoid dexamethasone to primary hepatocytes increases Tdo2 activity ([@bib66], [@bib71]) and mRNA levels ([@bib65], [@bib70], [@bib78]). Acute stress also increases hepatic Tdo2 activity ([@bib11], [@bib26], [@bib72], [@bib77]), an effect either reportedly requiring ([@bib11]) or only partly moderated by adrenal secretions ([@bib72], [@bib77]). Collectively, these data suggest hepatic Tdo2 activity is increased in a glucocorticoid-dependent (stress, corticosterone-induced) and glucocorticoid-independent (direct hypothalamic stimulation) manner.

Whether glucocorticoids directly mediate the upregulation of all three Tdo2 transcripts in the brain is unlikely since dexamethasone only upregulated Tdo2-FL in brain-slice cultures ([@bib7]). Thus, Tdo2-FL induction likely represents the adrenal-dependent transcript in the aforementioned studies, whereas Tdo2-v1 and Tdo2-v2 represent the adrenal/glucocorticoid-[in]{.ul}dependent transcripts. Again, it appears that tissues utilize different DO transcripts to fine-tune responses to specific physiologic inputs. Defining the Tdo2 transcriptome within specific hepatic cell-types is needed to completely understand Tdo2 (and Ido) regulation in response to stress.

Following acute stress, only the glucocorticoid-responsive Tdo2-FL transcript was induced within astrocytes. Curiously, the stress-induced increase in Tdo2-FL was preserved in astrocytes of Ido1^KO^ mice but not within whole-brain homogenate of Ido1^KO^ mice ([Fig. 6](#fig6){ref-type="fig"}A). Thus, although genetic deletion of Ido1 blocks stress-induced increases of astrocyte Ido2-v3 ([Fig. 5](#fig5){ref-type="fig"}B), astrocyte Tdo2-FL expression is still increased by stress in Ido1^KO^ mice ([Fig. 6](#fig6){ref-type="fig"}A). Hence, in astrocytes, the induction of Ido2 is Ido1-dependent, but the induction of Tdo2 is Ido1-[in]{.ul}dependent. Tdo2 (unknown transcript) is present primarily in neurons and astrocytes ([@bib55]). The stress-induced increase in Tdo2-v1 and Tdo2-v2 in whole brain is not seen in astrocytes (or microglia). Presumably, this induction is occurring within neurons and surprising requires Ido1 ([Fig. 6](#fig6){ref-type="fig"}). Elevated Tdo2 in neurons and astrocytes, along with elevated KynA, is a hallmark of schizophrenia ([@bib19], [@bib61]). Stress-induced Tdo2 may provide the comorbidity link between stress and schizophrenic development and psychosis ([@bib35], [@bib96]).

4.6. Downstream Kynurenine Pathway genes and their regulation by stress {#sec4.6}
-----------------------------------------------------------------------

The enzymatic machinery downstream of the DOs define the cellular-specificity of Kyn metabolism into neuroactive kynurenines ([@bib12], [@bib55]). Astrocytes expressed significantly more Kat2 and less Kynu, Kmo and Haao than microglia ([Fig. 7](#fig7){ref-type="fig"}A--D). Thus, downstream of the DOs, the relative expression levels of *Kynurenine Pathway* enzymes within astrocytes and microglia support current dogma which holds that astrocytes predominately produce KynA ([@bib28], [@bib33], [@bib42], [@bib55], [@bib83]) and microglia produce 3-HK and QuinA ([@bib30], [@bib34], [@bib55]). Although there are 3 well-characterized Kat enzymes, Kat2 is believed to account for the majority of KynA production in the mammalian brain ([@bib85]). Whether Kat1, Kat2 or Kat3 or their mRNA isoforms are differentially regulated in the brain or liver in response to stress is not known and outside the scope of the current project.

Downstream *Kyn Pathway* enzymes are spatially and temporally regulated in the brain by inflammation ([@bib80]) and acute stress ([@bib94]). Following acute stress, we found minor changes in the expression of these enzymes, such as the increase in astrocyte and microglia KMO. Nonetheless, the DOs are considered rate-limiting and DO expression was increased by acute stress in astrocytes ([Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"}). Both acute and chronic stress increase brain KynA ([@bib13], [@bib81]) despite unchanging Kat2 expression ([Fig. 7](#fig7){ref-type="fig"}). These findings suggest that the increase in KynA is controlled by elevated astrocyte DO expression without a necessary increase in Kat2. In contrast to the mild inductions by stress, acute LPS-induced inflammatory responses cause 2--5 fold increases in KMO expression (dependent on brain region) without induction of Haao or Kynu in the mouse brain and small changes in Kat2 expression ([@bib80]). These inflammatory responses suggest more robust changes in microglial downstream enzymes during neuroinflammation compared to stress.

The relevance of these findings to human well-being remains conjectural. The *Kynurenine Pathway* is implicated in mediating symptoms of depression induced by chronic stress and inflammation ([@bib75]). Increased plasma Kyn and cerebral spinal fluid levels of Kyn and QuinA are associated with depression symptomology in patients treated with IFNα ([@bib84]). In adolescents, the peripheral Kyn:Trp ratio correlates with anhedonia scores ([@bib25]) and increased suicidality ([@bib5]). These findings have been largely attributed to altered IDO1 activity ([@bib55]) with little known regarding the role of IDO2. In contrast, evidence is building for TDO2 involvement in human mental health.

White-matter astrocyte TDO2 immune staining was increased in *post mortem* frontal cortex and anterior cingulate samples of Schizophrenic patients compared to controls ([@bib61], [@bib60]). Schizophrenic patients have elevated salivary ([@bib9]), cerebrospinal fluid ([@bib86]) and frontal cortex levels of KynA ([@bib86]). Tdo2 mRNA expression in frontal cortex ([@bib60]) and anterior cingulate ([@bib61]) are greater *post mortem* in Schizophrenic patients than controls. One hallmark of Schizophrenia is the reduced ability of a 'prepulse' (or weak cue) to inhibit the natural startle response to a subsequent stronger stimulus ([@bib46]). Prepulse inhibition is also disrupted by increased brain KynA following peripheral administration of Kyn to rodents ([@bib18]). Within the brain, KynA reduces neurotransmitter activity by antagonizing α~7~nACh ([@bib98]) and NMDA receptors ([@bib30]). Acute stress increases urinary ([@bib20]) and salivary ([@bib9]) KynA levels in healthy volunteers. Acute stress also increases salivary KynA in Schizophrenic patients and greater KynA levels correlated with greater disease severity ([@bib9]). However, we are unaware of studies quantifying stress effects on central levels of KynA in humans. Nonetheless, mitigating stress ([@bib9], [@bib96]) and targeting astrocyte DOs and/or KAT are proposed as a therapeutic approaches for treating Schizophrenia ([@bib19], [@bib75], [@bib82]). While astrocyte Tdo2 is stress-sensitive in rodents and implicated in mediating increased central KynA in patients and rodent models of Schizophrenia, the expression of alternative DO transcript in humans following stress and in the pathogenesis of Schizophrenia remain totally un-defined.

5. Conclusion {#sec5}
=============

Although several studies have implicated the *Kynurenine Pathway* in stress-induced depression-like behavior, the cellular-origin and transcript-specificity of the DOs remained undefined. Herein, we report that all three DOs were upregulated by stress in a cell- and transcript-specific manner. Specifically, Ido1-v1, Ido2-v3 and Tdo2-FL were all increased in astrocytes. In contrast, brain Tdo2-v1 and Tdo2-v2 were upregulated by stress, a response that is [in]{.ul}dependent of astrocyte or microglial expression. When only investigating whole-brain or brain-regions these subtle but critical changes are easily overlooked. Remarkably, stress did not increase several DO transcripts in brain of Ido1^KO^ mice, suggesting an Ido1 requirement for their induction. Thus, our data highlight a significant perturbation of Ido2 and Tdo2 regulation within the brain of Ido1^KO^ mice. The specific role for astrocytes in acute stress is supported by reports of stress-induced increases in central kynurenic acid (KynA) ([@bib13], [@bib41], [@bib81]), the major downstream *Kynurenine Pathway* product produced by astrocytes ([@bib28], [@bib42], [@bib102]). Future studies examining the effect of stress on the *Kynurenine Pathway* should consider the role of all three DOs and examine cell-specific changes. Undoubtedly, a single qPCR assay will frequently miss cell-specific changes in DO expression.

Appendix A. Supplementary data {#appsec1}
==============================

The following is the supplementary data related to this article:Fig. S1**Additional Ido2 transcripts and their expression following acute stress**. Tissue and glia from control (Ctrl) and restraint-stressed (Res) mice sacrificed 2 h after a 3 h restraint were analyzed for additional Ido2 transcripts. **(A)** Ido2-v1 expression in brain is greater than astrocyte and microglia levels, indicating these cell-types are not the major source of Ido2-v1. Hypothalamic Ido2-v1 expression was greater than all other brain-regions. Stress slightly decreased Ido2-v1 relative to controls in the striatum. Ido2-v1 expression was not detectable in the liver. **(B)** Ido2-v2 expression was greater in microglia than brain with brain and astrocytes having similar expression levels, indicating that microglia and astrocytes are a major source of central Ido2-v2. In Ido1^KO^ mice, Ido2-v2 was greater in astrocytes compared to brain, and increased in the brain following restraint-stress relative to Ctrl. Within brain-regions, Ido2-v2 expression differed with Hypo \> PFC = Stri \> Hippo \> liver. Hypo Ido2-v2 was increased ∼28% by stress relative to Ctrl. **(C)** Ido2-v5 expression did not differ in brain, astrocytes or microglia of Ctrl or stressed mice, indicating a uniform expression pattern for this transcript. Ido2-v5 expression in the hypothalamus was greater than all other brain-regions. Hepatic Ido2-v5 expression was not detected. Ido2-v5 expression was not detected in brain or astrocytes of Ido1^KO^ mice. **(D)** Brain Ido2-v6 expression was greater than astrocyte and microglia, indicating these cell-types are not the major source of brain Ido2-v6. In Ido1^KO^ mice, brain Ido2-v6 expression was also greater than astrocyte levels. Ido2-v6 expression was greater in Hypo than all other brain-regions. Hepatic Ido2-v6 was not detectable. **(E)** Ido2-v7 expression did not differ in brain, astrocytes or microglia of Ctrl or stressed mice or across brain-regions, indicating a uniform expression pattern for this transcript. Ido2-v7 was not detected in Ido1^KO^ mice brain or astrocytes. Hepatic Ido2-v7 expression levels were greater than all other brain-regions. **(F)** Ido2-v8 expression was only detected in liver. \*p \< 0.05 comparing Ctrl to Res samples within tissue or glia. ^ϕ^p\<0.05 compared to other brain-regions. ^δ^p\<0.05 liver compared to all brain-regions.**Overall** these additional Ido2 transcripts are relatively impervious to stress. However, Ido2 transcripts fall into two general categories: **1)** hepatic expression \> than brain (Ido2-FL, Ido2-v3, Ido2-v4 ([Fig. 5](#fig5){ref-type="fig"}), Ido2-v7 and Ido2-v8 (Fig. S1); **2)** brain expression \> than liver (Ido2-v1, Ido2-v2, Ido2-v5 and Ido2-v6 (Fig. S1). This illustrates a distinct regulatory mechanism driving the expression of Ido2, albeit with as yet unrecognized functional consequences.Figure S1
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[^1]: Ido2-v5 and Ido2-v6 sequences lie within Ido2-v2 (thus it is not possible to design an assay specific to Ido2-v5 or Ido2-v6 that does not also quantify Ido2-v2). We have data indicating distinct differences in the regulation of these three transcripts ([@bib6]). Tdo2-FL\'s complete sequence lies within Tdo2-v1 (thus it is not possible to design an assay specific to Tdo2-FL that does not also quantify Tdo2-v1). Our current and published ([@bib6], [@bib7]) data show distinct differences in the expression and regulation of Tdo2-FL and Tdo2-v1, indicating that they are distinctly expressed transcripts. Names for Ido2-v3:Δ4, Tdo2-FL/-v1/-v2 and Tdo2 exon 0a and 0b exon designations are shown in an attempt to agree with published nomenclature ([@bib37], [@bib59]). Specifics shown for each qPCR assay include transcript location, catalog numbers (Mm.PT ...) or our custom assay names, primer/probe sequences and confirmed amplicon sizes.
